How Cancer Develops: Cell Growth and Mutations

Cancer arises when the molecular controls governing cell division break down, allowing abnormal cells to proliferate without the restraints that govern healthy tissue. Understanding how this process unfolds — from a single genetic error to an invasive mass — is foundational to every aspect of oncology, from screening guidelines to therapeutic design. This page covers the biological mechanisms of tumor formation, the types of mutations involved, the stages of malignant progression, and the boundaries that distinguish reversible cellular changes from established cancer.

Definition and scope

A cancer begins as a transformation in a single cell. Under normal conditions, the approximately 37 trillion cells in the human body replicate according to tightly regulated signals, repair DNA damage through dedicated enzymatic pathways, and undergo programmed death (apoptosis) when irreparably damaged. Cancer is the failure of these three systems — proliferation control, DNA repair, and apoptosis — occurring within the same cell lineage over time.

The National Cancer Institute (NCI) defines cancer as a collection of related diseases in which cells divide uncontrollably and spread into surrounding tissues. This definition encompasses more than 100 distinct disease types, each characterized by the tissue of origin, the specific driver mutations present, and the tumor's behavior relative to adjacent structures.

The scope of this problem is substantial. The NCI's Surveillance, Epidemiology, and End Results (SEER) Program estimates that approximately 40% of men and women in the United States will be diagnosed with cancer at some point in their lifetime, based on 2017–2019 data. That breadth reflects the universality of the underlying biology — every dividing cell carries mutation risk.

Understanding the mechanisms described on this page also connects directly to the regulatory context for oncology, because drug approvals, biomarker testing requirements, and clinical trial frameworks are all structured around the molecular targets that drive cancer development.

How it works

The role of DNA mutations

Cancer is fundamentally a disease of DNA. Mutations accumulate in genes that regulate cell behavior, and when those mutations affect critical control points, cells begin to behave autonomously. The National Human Genome Research Institute (NHGRI) categorizes the genetic drivers of cancer into two primary classes:

1. Oncogenes — genes that, when mutated or overexpressed, actively promote cell division. The RAS family of genes, mutated in roughly 30% of all human cancers (NCI), exemplifies this class. A single point mutation in KRAS can lock the encoded protein in a permanently active state, continuously signaling cells to divide.

2. Tumor suppressor genes — genes whose normal function is to restrain cell growth or trigger apoptosis. When both copies of a tumor suppressor are inactivated (following the "two-hit hypothesis" first described by Alfred Knudson in 1971), that brake on proliferation is lost. TP53, which encodes the protein p53, is altered in more than 50% of human cancers (NCI).

A third category, DNA repair genes (such as BRCA1 and BRCA2), does not directly drive proliferation but allows secondary mutations to accumulate uncorrected, accelerating the progression toward malignancy.

Multistep carcinogenesis

No single mutation typically produces cancer. The prevailing model, supported by decades of research and outlined in publications from the American Association for Cancer Research (AACR), describes carcinogenesis as a multistep process with three recognized phases:

1. Initiation — a mutagenic event (chemical carcinogen, ionizing radiation, viral integration, or replication error) produces a heritable DNA alteration in a single cell.
2. Promotion — the initiated cell receives sustained signals — often from chronic inflammation, hormonal exposure, or repeated tissue injury — that stimulate clonal expansion without necessarily introducing new mutations.
3. Progression — additional mutations accumulate within the expanding clone, producing subpopulations with increasingly aggressive traits: resistance to apoptosis, capacity for local invasion, and eventually the ability to enter the vasculature and metastasize.

Hallmarks of cancer

In 2000, researchers Douglas Hanahan and Robert Weinberg published "The Hallmarks of Cancer" in the journal Cell, identifying six core biological capabilities acquired during multistep development. A 2011 update added four additional hallmarks, bringing the total to 10 recognized capabilities. These include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. This framework is widely used by the NCI and AACR to organize therapeutic targets.

Common scenarios

Different cancers follow recognizable mutation patterns tied to their tissue of origin and primary carcinogenic exposures.

Tobacco-related lung carcinogenesis involves repeated exposure to approximately 70 known carcinogens in tobacco smoke (NCI), producing mutations in TP53, KRAS, and STK11, among others. Non-small cell lung cancer (NSCLC) accounts for roughly 85% of lung cancer diagnoses and typically accumulates 10 or more driver mutations before clinical detection.

UV radiation and skin cancer follows a well-characterized pathway in which ultraviolet-B radiation causes pyrimidine dimer formation in keratinocyte DNA. If repair pathways fail, characteristic C→T mutations at dipyrimidine sites arise in genes including CDKN2A and TP53, progressing toward squamous cell or basal cell carcinoma. Melanoma, arising from melanocytes, frequently carries BRAF V600E mutations, present in approximately 50% of cutaneous melanomas (American Cancer Society).

Hereditary cancer syndromes demonstrate that germline (inherited) mutations can dramatically compress the multistep timeline. Individuals with germline BRCA1 mutations carry a lifetime breast cancer risk of 55–72% and ovarian cancer risk of 44–46%, compared to population baseline risks of approximately 13% and 1–2%, respectively (National Comprehensive Cancer Network (NCCN)). Understanding inherited risk is a central reason genetic testing for cancer risk has become a standard clinical tool.

Chronic inflammation and gastrointestinal cancers illustrate the promotion phase in practice. In Barrett's esophagus, sustained acid exposure produces metaplastic changes across a progression from low-grade dysplasia to high-grade dysplasia to esophageal adenocarcinoma — a sequence that can span 10 to 15 years and provides multiple intervention windows.

Decision boundaries

Not every mutation produces cancer, and not every abnormal cellular state represents malignancy. Precise classification boundaries have regulatory and clinical significance.

Benign vs. malignant

The fundamental distinction explored in depth at benign vs. malignant tumors rests on two criteria:

• Invasiveness — malignant tumors breach the basement membrane and infiltrate adjacent tissues; benign tumors remain encapsulated or well-demarcated.
• Metastatic capacity — malignant cells can disseminate through lymphatic or hematogenous routes to distant sites; benign cells do not.

Histological grading by a pathologist — using criteria established by the College of American Pathologists (CAP) and reflected in pathology reports — provides the authoritative classification.

Pre-malignant and in situ states

Pre-malignant conditions (dysplasia, carcinoma in situ) represent intermediate states in the progression model. Carcinoma in situ carries malignant cytology but has not breached the basement membrane, placing it at the boundary where intervention can prevent invasive disease. The American Joint Committee on Cancer (AJCC) staging system assigns Stage 0 to in situ lesions, distinguishing them from Stage I through Stage IV invasive disease (see cancer staging and grading).

Somatic vs. germline mutations

A critical classification boundary for risk assessment and treatment:

The distinction has regulatory implications: germline testing falls under genetic counseling frameworks referenced by the Centers for Disease Control and Prevention (CDC) Office of Genomics and Precision Public Health, while somatic profiling for treatment selection is governed by FDA companion diagnostic requirements tied to specific drug approvals.

When cellular change does not equal cancer

Hypertrophy (increased cell size), hyperplasia (increased cell number), and metaplasia (cell type switching) are adaptive responses that do not necessarily progress to malignancy. Only when dysplasia — disordered growth with architectural and nuclear atypia — is confirmed histologically does the lesion enter the pre-malignant category. This distinction determines screening frequency, biopsy decisions, and surveillance intervals across guidelines published by the [U.S. Preventive Services Task Force (USP

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)